Leflunomide prevents the development of experimentally induced myasthenia gravis
- 1 April 1995
- journal article
- Published by Elsevier in International Journal of Immunopharmacology
- Vol. 17 (4) , 273-281
- https://doi.org/10.1016/0192-0561(95)00009-q
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Effect of leflunomide on constitutive and inducible pathways of cellular eicosanoid generationInflammation Research, 1994
- Prevention of the acute graft-versus-host disease (GVHD) in rats by the immunomodulating drug leflunomideAnnals of Hematology, 1994
- Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomideFEBS Letters, 1993
- Effects of leflunomide (HWA 486) on expression of lymphocyte activation markersInflammation Research, 1993
- A Clinical Therapeutic Trial of Cyclosporine in Myasthenia GravisaAnnals of the New York Academy of Sciences, 1993
- LEFLUNOMIDE, A NOVEL IMMUNOSUPPRESSIVE AGENTTransplantation, 1993
- Thymus Changes in Experimentally InducedAutoimmunity, 1993
- Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejectionInflammation Research, 1991
- Leflunomide (HWA 486) inhibits experimental autoimmune tubulointerstitial nephritis in ratsInternational Journal of Immunopharmacology, 1989
- Immunopharmacological profile of HWA 486, a novel isoxazol derivative— II. In vivo immunomodulating effects differ from those of cyclophosphamide, prednisolone, or cyclosporin AInternational Journal of Immunopharmacology, 1986